Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.57 |
| ▸ | RELA | Q04206 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | F12 | P00748 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.40 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.40 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944209 | 0.82 | RAB9A (0.43) | NFKB1NFKB2RELAMAOBMAOA | |
| SCHEMBL2943399 | 0.78 | NFKB1 (0.51) | NFKB1NFKB2RELAMAOBTACR1 | |
| SCHEMBL2953245 | 0.74 | TACR1 (0.43) | NFKB1NFKB2RELATACR1P2RX1 | |
| SCHEMBL3966246 | 0.72 | TACR1 (0.52) | TACR1P2RX1AKR1C3AKR1C2RAB9A | |
| SCHEMBL7583043 | 0.71 | TACR1 (0.51) | TACR1P2RX1AKR1C3AKR1C2RAB9A | |
| SCHEMBL18305334 | 0.68 | ALDH1A1 (0.43) | NFKB1NFKB2RELAMAOBMAOA | |
| SCHEMBL3990717 | 0.68 | TACR1 (0.45) | TACR1P2RX1AKR1C3AKR1C2TRPA1 | |
| SCHEMBL1639175 | 0.68 | NPC1 (0.43) | NFKB1NFKB2RELAMAOBMAOA | |
| SCHEMBL7997523 | 0.68 | NPC1 (0.43) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7575853 | 0.68 | TACR1 (0.47) | TACR1P2RX1AKR1C3AKR1C2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1596852-B1 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-05-27 | — | — | EP | claimed |
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2006-02-02 | — | — | US | claimed |
| EP-1596852-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| WO-2004071380-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2004-08-26 | — | — | WO | claimed |
| US-7754754-B2 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| EP-1596852-B1 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| EP-1596852-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004071380-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | AADAT, DDC, AADAC | NFKB1 2212/4885NFKB2 2503/4885RELA 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.